(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.09%.
Orchestra Biomed Holdings's earnings in 2025 is -$69,699,000.On average, 4 Wall Street analysts forecast OBIO's earnings for 2025 to be -$97,928,479, with the lowest OBIO earnings forecast at -$111,147,475, and the highest OBIO earnings forecast at -$90,104,992. On average, 4 Wall Street analysts forecast OBIO's earnings for 2026 to be -$85,114,147, with the lowest OBIO earnings forecast at -$94,960,950, and the highest OBIO earnings forecast at -$73,918,466.
In 2027, OBIO is forecast to generate -$70,141,611 in earnings, with the lowest earnings forecast at -$70,141,611 and the highest earnings forecast at -$70,141,611.